The diagnosis and treatment of multidrug-resistant (MDR) gram-negative bacteria in critically ill patients present many clinical challenges. Selection of appropriate antibiotic therapy in a timely manner requires patients’ comprehensive medical history, updated local knowledge of microbiological epidemiology, efficient use of diagnostic tools, and balancing of information from clinical trial data, real-world evidence (RWE), and guidelines.
In a symposium Pfizer organized in conjunction with the Asia Pacific Intensive Care Symposium (APICS), Professor David Paterson from the National University of Singapore discussed the importance of RWE in the antibiotic armamentarium, using ceftazidime-avibactam (CAZ-AVI, Zavicefta®) as an example. Dr Asok Kurup, Consultant Infectious Diseases Physician at Mount Elizabeth Medical Centre, Singapore, explained how rapid diagnostics can guide treatment choices to improve patient outcomes in MDR gram-negative infections.
Two target trials were emulated to compare the effectiveness of third doses of mRNA-based COVID-19 vaccines among US veteran population and across at-risk US veteran populations.